Biocept Launches Selector(TM), a Blood Based Test for EGFR

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients

SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC ), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced the launch of its EGFR mutation test that targets a region of the gene that includes T790M, a biomarker that identifies therapy-resistant tumors utilizing its proprietary Selector technology. This test will be performed at the Company's CLIA-certified and CAP-accredited laboratory and is the first of several assays the company will launch based on its proprietary Selector platform. The launch of Selector technology for ctDNA biomarker analysis from plasma in non-small cell lung cancer (NSCLC) expands Biocept's existing test menu of commercialized blood based assays for CTC capture and analysis for breast, gastric and lung cancers. The Selector technology was developed and validated by scientists at Biocept.

Approximately 20 percent of the NSCLC cases diagnosed each year are identified as EGFR-mutant, a correlation which has led to a number of targeted therapies focused on the patient population whose tumor has this mutation. These targeted therapies are known as Tyrosine Kinase Inhibitors, or TKIs. TKIs have been shown to be effective at shrinking tumors for a time, however, many patients ultimately develop resistance to EGFR-targeted TKIs because of secondary mutations such as T790M. Evaluating and monitoring for these secondary mutations in a clinical setting utilizing a blood sample could enhance the way treatment is managed. In addition to better informing clinicians when and how to treat NSCLC with TKIs, there are promising new therapies in clinical testing that target resistance alterations like T790M.

"Monitoring for EGFR resistance mutations in ctDNA from patients being treated with TKIs has the potential to dramatically change how physicians treat patients," said Veena Singh, M.D., Biocept SVP and Senior Medical Director. "High concordance when comparing tissue to blood samples demonstrates the feasibility of using this strategy in a clinical setting."

"In addition to being a noninvasive method to collect tumor related samples, blood testing could overcome the frequent obstacle of lack of sufficient tissue for molecular testing as well as issues with tumor heterogeneity. We believe these are significant advantages to our technology when testing gene mutations such as T790M," Singh said. 

"We are excited to launch our first test using our proprietary Selector technology," said Lyle Arnold Ph.D., Biocept SVP and Chief Scientific Officer. "Physicians and researchers know us as a leader in CTC capture and analysis. With Selector, we can help patients by analyzing molecular biomarkers in blood from both CTCs and ctDNA found in plasma. The significant sensitivity of Selector allows us to identify these rare cancer mutations shed by the tumor into the blood, even when a large excess of normal DNA is present."

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR™ test for breast cancer, OncoCEE-GA™ test for gastric cancer and OncoCEE-LU™ for non-small cell lung cancer and plans to introduce CLIA validated tests for melanoma, colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to improvement of outcomes, our impact on diagnostic strategies and planned future product offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov .

Investor Contact: The Ruth Group David Burke (646) 536-7009 Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 257

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 15

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 138

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 297

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 0

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 25

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 26

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading

Top 5 Most Recently Viewed Articles

HydrogenPro ASA Reports Strong Q4 2024 Financial Insights

Updated Category News Views 205

HydrogenPro ASA's Financial Results Overview HydrogenPro ASA (OSE: HYPRO) recently revealed its remarkable financial outcomes for the fourth quarter of 2024, showcasing a solid performance despite the challenges faced in the industry. This quarter highlights the company’s resilience and strengthens its position in the global hydrogen market. Key Achievements in Q4 2024...

Continue Reading
Angioplasty Balloons Market: $3.6B by 2033? Unpack the Growth!

Updated Category News Views 174

February 18, 2026—mark it down: the angioplasty balloons market is gearing up to swell from a cool $2.6 billion in 2023 to a whopping $3.6 billion by 2033 at a steady CAGR of 3.4%. Why? Well, take your pick: rising cardiovascular disease prevalence, a geriatric boom, and increasingly tech-savvy procedures are all fueling this surge. What’s Pumping Up Growth?...

Continue Reading
Norges Bank Transitions to Major Shareholder in NKT A/S

Updated Category News Views 175

Significant Shareholding Changes in NKT A/S In a recent announcement that has stirred interest in the investment community, it has come to light that Norges Bank has increased its holdings in NKT A/S. This announcement is significant as it illustrates the dynamic changes within major shareholding structures in public companies. Understanding the Acquisition NKT A/S has...

Continue Reading
Novo Nordisk Strengthens Shareholder Value with Buyback Plan

Updated Category News Views 103

Introduction to Novo Nordisk's Share Repurchase Program Leading healthcare company Novo Nordisk has embarked on an ambitious share repurchase program to strengthen its shareholder value. This initiative, aligning with European financial regulations, showcases the company's commitment to enhancing shareholder returns. The overall plan involves a substantial repurchase...

Continue Reading
Unlocking Potential: Monthly Dividend Strategies for Retirement

Updated Category News Views 189

Maximizing Monthly Income for Retirement Imagine enjoying monthly dividends that accumulate annual yields ranging from 7.2% to 15.4%. It’s enticing, especially for those looking for a steady stream of income during retirement. With the current market filled with uncertainty, many investors are skittish and hesitant to put their money into traditional investments. This...

Continue Reading